Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an update.
Shanghai Fosun Pharmaceutical has announced the first grant under its 2025 A Share Option Scheme, issuing 4,535,100 A Share Options to 195 participants. This grant, representing approximately 0.1698% of the company’s total shares, includes connected transactions exempt from further shareholder approval due to minimal percentage ratios, reflecting a strategic move to incentivize employees and align their interests with the company’s growth objectives.
The most recent analyst rating on (HK:2196) stock is a Sell with a HK$26.50 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development, manufacturing, and sale of pharmaceutical products, healthcare services, and medical devices, with a significant market presence in China.
Average Trading Volume: 9,801,390
Technical Sentiment Signal: Buy
Current Market Cap: HK$80.19B
Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.